Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

George J Netto

Showing results (211-220 of 315) with videos related to

Pageof 32
Sort By:
Cancer Immunology Research|June 8, 2017
Intravesical BCG Induces CD4<sup>+</sup> T-Cell Expansion in an Immune Competent Model of Bladder CancerMax Kates, Thomas Nirschl, Nikolai A Sopko, et al.
Human Pathology|December 3, 2014
Utility of uroplakin II expression as a marker of urothelial carcinomaWei Tian, Gunes Guner, Hiroshi Miyamoto, et al.
European Urology|October 6, 2022
Reply to Yongbao Wei, Haijian Huang, and Liefu Ye's Letter to the Editor re: George J. Netto, Mahul B. Amin, Daniel M. Berney, et al. The 2022 World Health Organization Classification of Tumors of the Urinary System and Male Genital Organs-Part B: Prostate and Urinary Tract Tumors. Eur Urol. 2022;82:469-82Mark A Rubin, Mahul B Amin, Eva Compérat, et al.
CA: a Cancer Journal for Clinicians|June 9, 2016
Current concepts in the diagnosis and pathobiology of intraepithelial neoplasia: A review by organ systemLysandra Voltaggio, Ashley Cimino-Mathews, Justin A Bishop, et al.
Urologic Oncology|March 28, 2015
Gemcitabine and cisplatin neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma: Predicting response and assessing outcomesNilay M Gandhi, Alexander Baras, Enrico Munari, et al.
Human Pathology|April 27, 2019
Tumor immune microenvironment in non-muscle-invasive urothelial carcinoma of the bladderMarie-Lisa Eich, Alcides Chaux, Gunes Guner, et al.
Annals of Surgical Oncology|March 26, 2016
Blood Transfusion is Associated with Increased Perioperative Morbidity and Adverse Oncologic Outcomes in Bladder Cancer Patients Receiving Neoadjuvant Chemotherapy and Radical CystectomyHeather J Chalfin, Jen-Jane Liu, Nilay Gandhi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 2011
PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patientsTamara L Lotan, Bora Gurel, Siobhan Sutcliffe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 11, 2013
Rb loss is characteristic of prostatic small cell neuroendocrine carcinomaHsueh-Li Tan, Akshay Sood, Hameed A Rahimi, et al.
Oncotarget|August 14, 2018
PD-L1 expression comparison between primary and relapsed non-small cell lung carcinoma using whole sections and clone SP263Enrico Munari, Giuseppe Zamboni, Gianluigi Lunardi, et al.
Pageof 32

Showing results (211-220 of 315) with videos related to

Sort By:
Pageof 32
Cancer Immunology Research|June 8, 2017
Intravesical BCG Induces CD4<sup>+</sup> T-Cell Expansion in an Immune Competent Model of Bladder CancerMax Kates, Thomas Nirschl, Nikolai A Sopko, et al.
Human Pathology|December 3, 2014
Utility of uroplakin II expression as a marker of urothelial carcinomaWei Tian, Gunes Guner, Hiroshi Miyamoto, et al.
European Urology|October 6, 2022
Reply to Yongbao Wei, Haijian Huang, and Liefu Ye's Letter to the Editor re: George J. Netto, Mahul B. Amin, Daniel M. Berney, et al. The 2022 World Health Organization Classification of Tumors of the Urinary System and Male Genital Organs-Part B: Prostate and Urinary Tract Tumors. Eur Urol. 2022;82:469-82Mark A Rubin, Mahul B Amin, Eva Compérat, et al.
CA: a Cancer Journal for Clinicians|June 9, 2016
Current concepts in the diagnosis and pathobiology of intraepithelial neoplasia: A review by organ systemLysandra Voltaggio, Ashley Cimino-Mathews, Justin A Bishop, et al.
Urologic Oncology|March 28, 2015
Gemcitabine and cisplatin neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma: Predicting response and assessing outcomesNilay M Gandhi, Alexander Baras, Enrico Munari, et al.
Human Pathology|April 27, 2019
Tumor immune microenvironment in non-muscle-invasive urothelial carcinoma of the bladderMarie-Lisa Eich, Alcides Chaux, Gunes Guner, et al.
Annals of Surgical Oncology|March 26, 2016
Blood Transfusion is Associated with Increased Perioperative Morbidity and Adverse Oncologic Outcomes in Bladder Cancer Patients Receiving Neoadjuvant Chemotherapy and Radical CystectomyHeather J Chalfin, Jen-Jane Liu, Nilay Gandhi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 2011
PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patientsTamara L Lotan, Bora Gurel, Siobhan Sutcliffe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 11, 2013
Rb loss is characteristic of prostatic small cell neuroendocrine carcinomaHsueh-Li Tan, Akshay Sood, Hameed A Rahimi, et al.
Oncotarget|August 14, 2018
PD-L1 expression comparison between primary and relapsed non-small cell lung carcinoma using whole sections and clone SP263Enrico Munari, Giuseppe Zamboni, Gianluigi Lunardi, et al.
Pageof 32